Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' TUCKER GT' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 83 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Allorge, D; Harlow, J; Boulet, O; Hayhurst, GP; Chowdry, J; Roth, E; Crewe, K; Lo-Guidice, JM; Lhermitte, M; Broly, F; Tucker, GT; Ellis, SW
      In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism

      PHARMACOGENETICS
    2. Johnson, TN; Tanner, MS; Taylor, CJ; Tucker, GT
      Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    3. Rostami-Hodjegan, A; Tucker, GT
      Journal impact factors: a 'bioequivalence' issue?

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    4. Hayhurst, GP; Harlow, J; Chowdry, J; Gross, E; Hilton, E; Lennard, MS; Tucker, GT; Ellis, SW
      Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6

      BIOCHEMICAL JOURNAL
    5. Tucker, GT
      Equivalence in disease states

      EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
    6. Forsyth, JT; Grunewald, RA; Rostami-Hodjegan, A; Lennard, MS; Sagar, HJ; Tucker, GT
      Parkinson's disease and CYP1A2 activity

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    7. Ellis, SW; Hayhurst, GP; Lightfoot, T; Smith, G; Harlow, J; Rowland-Yeo, K; Larsson, C; Mahling, J; Lim, CK; Wolf, CR; Blackburn, MG; Lennard, MS; Tucker, GT
      Evidence that serine 304 is not a key ligand-binding residue in the activesite of cytochrome P450 2D6

      BIOCHEMICAL JOURNAL
    8. Tucker, GT
      Advances in understanding drug metabolism and its contribution to variability in patient response

      THERAPEUTIC DRUG MONITORING
    9. Tucker, GT
      Chiral switches

      LANCET
    10. Coleman, T; Spellman, EF; Rostami-Hodjegan, A; Lennard, MS; Tucker, GT
      The 1 '-hydroxylation of rac-bufuralol by rat brain microsomes

      DRUG METABOLISM AND DISPOSITION
    11. Lightfoot, T; Ellis, SW; Mahling, J; Ackland, MJ; Blaney, FE; Bijloo, GJ; De Groot, MJ; Vermeulen, NPE; Blackburn, GM; Lennard, MS; Tucker, GT
      Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling

      XENOBIOTICA
    12. Johnson, TN; Tanner, MS; Tucker, GT
      A comparison of the ontogeny of enterocytic and hepatic cytochromes P450 3A in the rat

      BIOCHEMICAL PHARMACOLOGY
    13. Siy, HP; Herbsleb, JD; Mockus, A; Krishnan, M; Tucker, GT
      Making the software factory work: Lessons from a decade of experience

      SEVENTH INTERNATIONAL SOFTWARE METRICS SYMPOSIUM - METRICS 2001, PROCEEDINGS
    14. Rostami-Hodjegan, A; Kroemer, HK; Tucker, GT
      In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity

      PHARMACOGENETICS
    15. Schulz-Utermoehl, T; Bennett, AJ; Ellis, SW; Tucker, GT; Boobis, AR; Edwards, RJ
      Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression

      PHARMACOGENETICS
    16. Marez-Allorge, D; Ellis, SW; Lo Guidice, JM; Tucker, GT; Broly, F
      A rare G(2061) insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype

      PHARMACOGENETICS
    17. Manap, RA; Wright, CE; Gregory, A; Rostami-Hodjegan, A; Meller, ST; Kelm, GR; Lennard, MS; Tucker, GT; Morice, AH
      The antitussive effect of dextromethorphan in relation to CYP2D6 activity

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    18. Rostami-Hodjegan, A; Wolff, K; Hay, AWM; Raistrick, D; Calvert, R; Tucker, GT
      Population pharmacokinetics of methadone in opiate users: characterizationof time-dependent changes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    19. Rostami-Hodjegan, A; Funck-Brentano, C; Kroemer, HK; Tucker, GT
      In vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    20. Ghahramani, P; Jackson, PR; Tucker, GT
      Fraction of dose of drug converted to a metabolite when both compete for metabolism by the same enzyme

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    21. Forsyth, J; Grunewald, RA; Lennard, MS; Rostami-Hodjegan, A; Sagar, HJ; Tucker, GT
      Altered caffeine metabolism in patients with Parkinson's disease

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    22. Abdul-Manap, R; Wright, CE; Rostami-Hodjegan, A; Meller, S; Lennard, MS; Morice, AH; Tucker, GT
      Cytochrome P450 2D6 (CYP2D6) activity in relation to the antitussive effect of dextromethorphan

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    23. Rostami-Hodjegan, A; Forsyth, J; Grunewald, RA; Lennard, MS; Sagar, HJ; Tucker, GT
      The paraxanthine caffeine ratio in saliva as a marker of CYP1A2 activity

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    24. Segall, MD; Payne, MC; Ellis, SW; Tucker, GT; Eddershaw, PJ
      First principles investigation of singly reduced cytochrome P450

      XENOBIOTICA
    25. Marsh, JCW; Chowdry, J; Parry-Jones, N; Ellis, SW; Muir, KR; Gordon-Smith, EC; Tucker, GT
      Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia

      BRITISH JOURNAL OF HAEMATOLOGY
    26. SEGALL MD; PAYNE MC; ELLIS SW; TUCKER GT; BOYES RN
      FIRST PRINCIPLES CALCULATION OF THE ACTIVITY OF CYTOCHROME-P450

      Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics
    27. ROSTAMIHODJEGAN A; LENNARD MS; WOODS HE; TUCKER GT
      METAANALYSIS OF STUDIES OF THE CYP2D6 POLYMORPHISM IN RELATION TO LUNG-CANCER AND PARKINSONS-DISEASE

      Pharmacogenetics
    28. SEGALL MD; PAYNE MC; ELLIS W; TUCKER GT; BOYES N
      EVIDENCE FOR STABILIZATION OF THE LOW-SPIN STATE OF CYTOCHROME-P450 DUE TO SHORTENING OF THE PROXIMAL HEME BOND

      Chemical research in toxicology
    29. SIMOOYA OO; SIJUMBILA G; LENNARD MS; TUCKER GT
      HALOFANTRINE AND CHLOROQUINE INHIBIT CYP2D6 ACTIVITY IN HEALTHY ZAMBIANS (VOL 45, PG 315, 1998)

      British journal of clinical pharmacology
    30. SIMOOYA OO; SIJUMBIL G; LENNARD MS; TUCKER GT
      HALOFANTRINE AND CHLOROQUINE INHIBIT CYP2D6 ACTIVITY IN HEALTHY ZAMBIANS

      British journal of clinical pharmacology
    31. ROSTAMIHODJEGAN A; PEACEY SR; GEORGE E; HELLER SR; TUCKER GT
      POPULATION-BASED MODELING TO DEMONSTRATE EXTRAPANCREATIC EFFECTS OF TOLBUTAMIDE

      American journal of physiology: endocrinology and metabolism
    32. SEGALL MD; PAYNE MC; ELLIS SW; TUCKER GT; BOYES RN
      AN AB-INITIO APPROACH TO THE UNDERSTANDING OF CYTOCHROME-P450 LIGAND INTERACTIONS

      Xenobiotica
    33. Tucker, GT; Rostami-Hodjegan, A; Jackson, PR
      Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues

      XENOBIOTICA
    34. TUCKER GT
      STEREOSELECTIVITY IN DRUG-ACTION

      Naunyn-Schmiedeberg's archives of pharmacology
    35. ROSTAMIHODJEGAN A; WOLFF K; HAY AWM; CALVERT R; TUCKER GT
      POPULATION-KINETICS OF METHADONE IN OPIATE-USERS - CHARACTERIZATION OF TIME-DEPENDENT CHANGES

      Naunyn-Schmiedeberg's archives of pharmacology
    36. GHAHRAMANI P; DAVIES SJC; YEO WW; JACKSON PR; TUCKER GT; RAMSAY LE
      EFFECT OF CYP2D6 GENETIC-POLYMORPHISM ON SIDE-EFFECTS OF AMITRIPTYLINE AND NORTRIPTYLINE

      Clinical pharmacology and therapeutics
    37. SEGALL MD; PAYNE MC; ELLIS SW; TUCKER GT; BOYES RN
      AB-INITIO MOLECULAR MODELING IN THE STUDY OF DRUG-METABOLISM

      European journal of drug metabolism and pharmacokinetics
    38. WOLFF K; ROSTAMIHODJEGAN A; SHIRES S; HAY AWM; FEELY M; CALVERT R; RAISTRICK D; TUCKER GT
      THE PHARMACOKINETICS OF METHADONE IN HEALTHY-SUBJECTS AND OPIATE USERS

      British journal of clinical pharmacology
    39. BABER NS; TUCKER GT; WEBB DJ
      THE CLINICAL-SECTION OF THE BRITISH-PHARMACOLOGICAL-SOCIETY - PROSPECTS FOR THE FUTURE

      British journal of clinical pharmacology
    40. GHAHRAMANI P; ELLIS SW; LENNARD MS; RAMSAY LE; TUCKER GT
      CYTOCHROMES P450 MEDIATING THE N-DEMETHYLATION OF AMITRIPTYLINE

      British journal of clinical pharmacology
    41. BACK DJ; MCINNES GT; TUCKER GT
      NEW COVER - RENEWED COMMITMENT

      British journal of clinical pharmacology
    42. MARSH JCW; ELLIS SW; CHOWDRY J; PARRYJONES N; GORDONSMITH EC; TUCKER GT
      CYTOCHROMES P45-2D6 AND 2E1 MUTATIONS ARE NOT ASSOCIATED WITH AN INCREASED RISK OF IDIOSYNCRATIC APLASTIC-ANEMIA

      Experimental hematology
    43. LIN LY; DISTEFANO EW; SCHMITZ DA; HSU L; ELLIS SW; LENNARD MS; TUCKER GT; CHO AK
      OXIDATION OF METHAMPHETAMINE AND METHYLENEDIOXYMETHAMPHETAMINE BY CYP2D6

      Drug metabolism and disposition
    44. ROSTAMIHODJEGAN A; TUCKER GT
      IS C-MAX AUC USEFUL FOR BIOEQUIVALENCE TESTING/

      Journal of pharmaceutical sciences
    45. PEACEY SR; ROSTAMIHODJEGAN A; GEORGE E; TUCKER GT; HELLER SR
      THE USE OF TOLBUTAMIDE-INDUCED HYPOGLYCEMIA TO EXAMINE THE INTRAISLETROLE OF INSULIN IN MEDIATING GLUCAGON-RELEASE IN NORMAL HUMANS

      The Journal of clinical endocrinology and metabolism
    46. LENNARD MS; CREWE HK; ELLIS SW; TUCKER GT
      THE 4-HYDROXYLATION OF TAMOXIFEN BY HUMAN LIVER CYTOCHROMES P450 2D6,2C9 AND 3A4

      Clinical pharmacology and therapeutics
    47. CREWE HK; ELLIS SW; LENNARD MS; TUCKER GT
      VARIABLE CONTRIBUTION OF CYTOCHROMES P450 2D6, 2C9 AND 3A4 TO THE 4-HYDROXYLATION OF TAMOXIFEN BY HUMAN LIVER-MICROSOMES

      Biochemical pharmacology
    48. JENNINGS M; SWEETLAND H; SMITH CAD; WOLF CR; LENNARD MS; TUCKER GT; WOODS HF; ROGERS K
      LACK OF RELATIONSHIPS BETWEEN THE DEBRISOQUINE (CYP2D6) AND MEPHENYTION (CYP2C19) OXIDATION POLYMORPHISMS AND SUSCEPTIBILITY TO BREAST-CANCER

      Breast
    49. ROSTAMIHODJEGAN A; NURMINEN S; JACKSON PR; TUCKER GT
      CAFFEINE URINARY METABOLITE RATIOS AS MARKERS OF ENZYME-ACTIVITY - A THEORETICAL ASSESSMENT

      Pharmacogenetics
    50. PEACEY SR; GEORGE E; ROSTAMIHODJEGAN A; BEDFORD C; HARRIS N; HARDISTY CA; TUCKER GT; MACDONALD IA; HELLER SR
      SIMILAR PHYSIOLOGICAL AND SYMPTOMATIC RESPONSES TO SULFONYLUREA AND INSULIN-INDUCED HYPOGLYCEMIA IN NORMAL SUBJECTS

      Diabetic medicine
    51. WOLFF K; HAY AWM; SHIRES S; FEELY M; CALVERT R; ROSTAMIHODJEGAN A; TUCKER GT
      SINGLE-DOSE PHARMACOKINETICS OF METHADONE IN HEALTHY-SUBJECTS

      British journal of clinical pharmacology
    52. ROSTAMIHODJEGAN A; PEACEY SR; HELLER SR; TUCKER GT
      A PHARMACOKINETIC-PHARMACODYNAMIC MODEL TO EXPLAIN THE BIPHASIC INSULINERGIC EFFECT OF TOLBUTAMIDE AND THE SUPPRESSIVE ROLE OF LOWERING BLOOD-GLUCOSE ON THIS EFFECT

      British journal of clinical pharmacology
    53. PARK BK; KITTERINGHAM NR; PIRMOHAMED M; TUCKER GT
      RELEVANCE OF INDUCTION OF HUMAN DRUG-METABOLIZING-ENZYMES - PHARMACOLOGICAL AND TOXICOLOGICAL IMPLICATIONS (VOL 41, PG 477, 1996)

      British journal of clinical pharmacology
    54. ROWLAND K; ELLIS SW; LENNARD MS; TUCKER GT
      VARIABLE CONTRIBUTION OF CYP2D6 TO THE N-DEALKYLATION OF S-(-)-PROPRANOLOL BY HUMAN LIVER-MICROSOMES

      British journal of clinical pharmacology
    55. ELLIS SW; ROWLAND K; ACKLAND MJ; REKKA E; SIMULA AP; LENNARD MS; WOLF CR; TUCKER GT
      INFLUENCE OF AMINO-ACID RESIDUE-374 OF CYTOCHROME-P-450 2D6 (CYP2D6) ON THE REGIO-SELECTIVE AND ENANTIO-SELECTIVE METABOLISM OF METOPROLOL

      Biochemical journal
    56. BERESFORD AP; TAYLOR RJ; ASHCROFT JA; AYRTON J; TUCKER GT; ELLIS SW
      EXPRESSION OF HUMAN CYTOCHROME P4501A1 (CYP1A1) IN SACCHAROMYCES-CEREVISIAE INHIBITS CELL-DIVISION

      Xenobiotica
    57. COLEMAN T; ELLIS SW; MARTIN IJ; LENNARD MS; TUCKER GT
      1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) IS N-DEMETHYLATEDBY CYTOCHROMES P450 2D6, 1A2 AND 3A4 - IMPLICATIONS FOR SUSCEPTIBILITY TO PARKINSONS-DISEASE

      The Journal of pharmacology and experimental therapeutics
    58. ROSTAMIHODJEGAN A; PEACY SA; HELLER SR; TUCKER GT
      TOLBUTAMIDE ENHANCES GLUCOSE EFFECTIVENESS FOLLOWING ACUTE ADMINISTRATION IN NONDIABETIC SUBJECTS

      Diabetologia
    59. HELLER SR; ROSTAMIHODJEGAN A; PEACY SA; TUCKER GT
      FASTING INSULIN PREDICTS THE ACUTE INSULINERGIC EFFECT OF TOLBUTAMIDE, WHICH IS NOT RELATED TO HYPOGLYCEMIC EFFECT

      Diabetologia
    60. COLEMAN T; ELLIS SW; MARTIN IJ; LENNARD MS; TUCKER GT
      MPTP IS N-DEMETHYLATED BY CYPS 2D6, 1A2 AND 3A4 - IMPLICATIONS FOR SUSCEPTIBILITY TO PARKINSONS-DISEASE

      British Journal of Pharmacology
    61. TUCKER GT
      PERIOPERATIVE CHANGES IN ALPHA(1)-ACID GLYCOPROTEIN CONCENTRATIONS

      British Journal of Anaesthesia
    62. MACKMAN R; TSCHIRRETGUTH RA; SMITH G; HAYHURST GP; ELLIS SW; LENNARD RS; TUCKER GT; WOLF CR; DEMONTELLANO PRO
      ACTIVE-SITE TOPOLOGIES OF HUMAN CYP2D6 AND ITS ASPARTATE-301-]GLUTAMATE, ASPARAGINE, AND GLYCINE MUTANTS

      Archives of biochemistry and biophysics
    63. BRODEY BB; QUIRK MP; DAGADAKIS CS; KOEPSELL TD; TUCKER GT
      MENTAL-HEALTH BENEFIT DESIGN - STRIVING TO ACHIEVE PARITY IN WASHINGTON-STATE

      Psychiatric services
    64. GARDNER IB; WALKER DK; LENNARD MS; SMITH DA; TUCKER GT
      COMPARISON OF THE DISPOSITION OF 2 NOVEL COMBINED THROMBOXANE SYNTHASE INHIBITORS THROMBAXANE-A(2) RECEPTOR ANTAGONISTS IN THE ISOLATED-PERFUSED RAT-LIVER

      Xenobiotica
    65. ELLIS SW; HAYHURST GP; SMITH G; LIGHTFOOT T; WONG MMS; SIMULA AP; ACKLAND MJ; STERNBERG MJE; LENNARD MS; TUCKER GT; WOLF CR
      EVIDENCE THAT ASPARTIC-ACID-301 IS A CRITICAL SUBSTRATE-CONTACT RESIDUE IN THE ACTIVE-SITE OF CYTOCHROME-P450 2D6

      The Journal of biological chemistry
    66. PEACEY SR; GEORGE E; ROSTAMI A; BEDFORD C; HARRIS N; HARDISTY CA; TUCKER GT; HELLER SR
      SIMILAR PHYSIOLOGICAL AND SYMPTOMATIC RESPONSES TO SULFONYLUREA AND INSULIN-INDUCED HYPOGLYCEMIA IN NORMAL SUBJECTS

      Diabetes
    67. INABA T; NEBERT DW; BURCHELL B; WATKINS PB; GOLDSTEIN JA; BERTILSSON L; TUCKER GT
      PHARMACOGENETICS IN CLINICAL-PHARMACOLOGY AND TOXICOLOGY

      Canadian journal of physiology and pharmacology
    68. CHING MS; BLAKE CL; GHABRIAL H; ELLIS SW; LENNARD MS; TUCKER GT; SMALLWOOD RA
      POTENT INHIBITION OF YEAST-EXPRESSED CYP2D6 BY DIHYDROQUINIDINE, QUINIDINE, AND ITS METABOLITES

      Biochemical pharmacology
    69. BULSARA D; ACKLAND MJ; DUNCAN JN; REES SA; ELLIS SW; LENNARD MS; TUCKER GT
      EVALUATION OF A TEMPLATE MODEL OF THE CYP2D6 ACTIVE-SITE BY EXPERIMENTAL TESTING OF COMPOUNDS WITH RECOMBINANT HUMAN CYP2D6

      The FASEB journal
    70. WEERASURIYA K; JAYAKODY RL; SMITH CAD; WOLF CR; TUCKER GT; LENNARD MS
      DEBRISOQUINE AND MEPHENYTOIN OXIDATION IN SINHALESE - A POPULATION STUDY

      British journal of clinical pharmacology
    71. ROWLAND K; YEO WW; ELLIS SW; CHADWICK IG; HAQ I; LENNARD MS; JACKSON PR; RAMSAY LE; TUCKER GT
      INHIBITION OF CYP2D6 ACTIVITY BY TREATMENT WITH PROPRANOLOL AND THE ROLE OF 4-HYDROXY PROPRANOLOL

      British journal of clinical pharmacology
    72. WALLER PC; JACKSON PR; TUCKER GT; RAMSAY LE
      CLINICAL-PHARMACOLOGY WITH CONFIDENCE

      British journal of clinical pharmacology
    73. TUCKER GT
      THE INTERACTION OF PROTON PUMP INHIBITORS WITH CYTOCHROMES P450

      Alimentary pharmacology & therapeutics
    74. TUCKER GT
      SAFETY IN NUMBERS - THE ROLE OF PHARMACOKINETICS IN LOCAL-ANESTHETIC TOXICITY - THE 1993 ASRA LECTURE

      Regional anesthesia
    75. WILLIAMS ML; LENNARD MS; MARTIN IJ; TUCKER GT
      INTERINDIVIDUAL VARIATION IN THE ISOMERIZATION OF 4-HYDROXYTAMOXIFEN BY HUMAN LIVER-MICROSOMES - INVOLVEMENT OF CYTOCHROMES P450

      Carcinogenesis
    76. TUCKER GT
      CLINICAL IMPLICATIONS OF GENETIC-POLYMORPHISM IN DRUG-METABOLISM

      Journal of Pharmacy and Pharmacology
    77. ROSTAMIHODJEGAN A; JACKSON PR; TUCKER GT
      SENSITIVITY OF INDIRECT METRICS FOR ASSESSING RATE IN BIOEQUIVALENCE STUDIES - MOVING THE GOALPOSTS OR CHANGING THE GAME

      Journal of pharmaceutical sciences
    78. ELLIS SW; ROWLAND K; HARLOW JR; SIMULA AP; LENNARD MS; WOODS HF; TUCKER GT; WOLF CR
      REGIOSELECTIVE AND ENANTIOSELECTIVE METABOLISM OF METOPROLOL BY 2 HUMAN CDNA-DERIVED CYP2D6 PROTEINS

      British Journal of Pharmacology
    79. BARHAM HM; LENNARD MS; TUCKER GT
      AN EVALUATION OF CYTOCHROME-P450 ISOFORM ACTIVITIES IN THE FEMALE DARK AGOUTI (DA) RAT - RELEVANCE TO ITS USE AS A MODEL OF THE CYP2D6 POORMETABOLIZER PHENOTYPE

      Biochemical pharmacology
    80. TUCKER GT; LENNARD MS; ELLIS SW; WOODS HF; CHO AK; LIN LY; HIRATSUKA A; SCHMITZ DA; CHU TYY
      THE DEMETHYLENATION OF METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) BY DEBRISOQUINE HYDROXYLASE (CYP2D6)

      Biochemical pharmacology
    81. WATTS AR; LENNARD MS; MASON SL; TUCKER GT; WOODS HF
      BEETURIA AND THE BIOLOGICAL FATE OF BEETROOT PIGMENTS

      Pharmacogenetics
    82. SIMOOYA OO; NJUNJU E; HODJEGAN AR; LENNARD MS; TUCKER GT
      DEBRISOQUINE AND METOPROLOL OXIDATION IN ZAMBIANS - A POPULATION STUDY

      Pharmacogenetics
    83. WHALLEY PM; TUCKER GT; REILLY CS
      EFFECT OF PROPOFOL ON PROPRANOLOL METABOLISM BY HUMAN LIVER-MICROSOMES

      British Journal of Anaesthesia


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/08/20 alle ore 18:09:17